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ABSTRACT 
Background 
Neutropenic enterocolitis (NE) is a life-threatening complication in patients undergoing intensive 
chemotherapy for hematological malignancies. Aims of this study were to analyze the clinical 
presentation, diagnostic findings, management and outcome of NE and to explore factors associated 
with adverse outcome. 
Methods 
This study describes the presentation and outcome of NE in hemato-oncological patients hospitalized 
for intensive chemotherapy in the isolation unit of the Infectious Diseases Service at CHUV in 2008 
and 2012. Cases were identified from the institutional database and clinical data retrospectively 
extracted from medical charts.  
Results 
32 out of 199 hemato-oncological patients (16.1%) presented 35 episodes of NE. According to 
predefined clinical and radiological/histopathological diagnostic criteria, NE was classified as definite 
in 14, probable in 19, and possible in 2 cases. Induction or induction-reinduction chemotherapy for 
acute myeloid leukemia was the most frequent hemato-oncological setting. The triad of neutropenia, 
fever and digestive symptoms was present in all patients. Bowel wall thickening > 4 mm at CT scan 
was found in 63.6% of cases. In 34.3% of episodes a bacterial bloodstream infection was documented. 
Despite a Candida gastrointestinal colonization in more than two thirds of cases, invasive candidiasis 
was documented in only two cases (5.7%). An adverse outcome was observed in 20% of patients: 4 
(11.4%) patients had severe sepsis, two (5.7%) septic shock, 6 (17.1%) were admitted to the ICU, one 
(3%) underwent an endoscopic intervention and recovered, and two patients died (5.7%): in one (3%) 
death was attributed to NE. High-dose cytarabine resulting in prolonged agranulocytosis and severe 
mucosal damage was associated with adverse outcome of NE. 
Conclusion 
This exploratory study reveals the determinant role of intensive chemotherapy for acute myeloid 
leukemia and especially of high-dose cytarabine in the occurrence of NE. The severe hematological 
and mucosal toxicity of this regimen are major components in the pathogenesis of NE and are 
associated with adverse outcome. These findings may help to identify patients at high risk for 
complications who need prompt management, close follow-up and maybe antimicrobial prophylaxis.   
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BACKGROUND 
Context 
Neutropenic enterocolitis (NE) is a severe complication, which is principally observed in patients 
undergoing intensive chemotherapy for hematological malignancies. NE less frequently occurs in 
patients with solid tumors or rare hematological conditions such as aplastic anemia, cyclic neutropenia 
or other diseases associated with absolute or functional neutropenia [1-3]. 
Incidence 
A NE incidence of 5.3 % has been reported in patients hospitalized for treatment of hematological 
malignancies, high-dose chemotherapy for solid tumors or aplastic anemia [4]. Among acute leukemic 
patients, incidence ranges from 1 % to 46 %, depending on the clinical settings [2, 3, 5].  
Pathophysiology 
Although the pathophysiology of NE is not completely elucidated, two major mechanisms contribute 
to its occurrence. The direct effect of cytotoxic agents on the rapidly dividing cells of the 
gastrointestinal mucosa is the first step in the pathogenesis of this complication [6]. The toxic damage 
of the physiological barrier results in the translocation of the bacterial and fungal endogenous flora, 
which underlies the selective pressure of previous antibacterial and antifungal treatments [2, 3, 5, 7]. 
As a crucial second step, the neutropenic state induced by the chemotherapy facilitates the microbial 
invasion of the bowel wall and the secondary hematogenous dissemination [2, 3, 5]. Some authors also 
consider thrombocytopenia-associated intramural bowel hemorrhage and leukemic or lymphomatous 
infiltration of the bowel wall as contributing components in the pathophysiology of NE [2, 7]. 
Although this pathogenetic process is classically reported in the ileocecal region (typhlitis), other 
segments of the gastrointestinal tract are often simultaneously involved (duodenitis, jejunitis, ileitis, 
colitis): thus, the use of the term NE is more appropriate [1].   
Risk factors 
There is few information in the literature about risk factors for developing NE. Cytosine arabinoside 
(ARA-C) treatment, especially at high dose, has been associated with a higher risk of presenting this 
complication [2, 3]. Moreover, a patient with NE is at risk for a recurrent episode in a subsequent 
chemotherapy cycle, which may suggest the role of immunogenetic factors in the pathogenesis [2, 3]. 
Clinical presentation, laboratory, radiological and pathological findings 
The typical clinical presentation of NE consists in fever, abdominal pain (sometimes localized in the 
right lower quadrant), abdominal distention, bloating, which are frequently associated with nausea, 
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vomiting, diarrhea, and, sometimes, with bloody stools. The physical examination shows diffuse 
tenderness, rebound guarding, peritoneal signs and a palpable mass, which can be localized in any 
abdominal quadrant [1-3, 5, 7, 9, 10]. Specific clinical diagnostic criteria are however lacking [1, 5, 9].  
The typical laboratory finding is prolonged profound neutropenia (agranulocytosis, i.e. neutrophil cell 
blood count < 0.1 G/l during more than 7 days). Neutrophils’ recovery is associated with a rapid 
improvement of the clinical status [3, 9].  
The reported rate of positive blood cultures in NE varies largely in the literature [2]. In their study, 
Gomes et al. reported positive blood cultures in 44 % of definite and 18 % of possible NE episodes 
[2]. Aerobic and anaerobic Gram-positive and Gram–negative bacteria as well as fungi such as 
Candida and Aspergillus have been described in NE, either as monomicrobial or as polymicrobial 
infections [1, 11]. 
Signs on conventional X-ray films of the abdomen are nonspecific and not sensitive for the diagnosis 
of NE. CT scan and ultrasonography of the abdomen are more accurate, in particular for detecting and 
quantifying bowel wall thickening (BWT) as a characteristic and prognostic radiological finding of 
NE [1, 9, 12-14]. 
The pathological findings of NE are characterized by lesions of the bowel wall ranging from mucosal 
inflammation to transmural necrosis [3, 15].  
Morbidity and mortality 
The reported mortality of NE is variable [1]: Gomes et al. observed a 22 % mortality rate [2] while 
Gorschlüter et al. found a 54 % rate [16]. NE with Clostridium septicum bloodstream infection has an 
especially poor outcome (mortality rate up to 50-100 %) [8]. 
Clinical management 
Conservative management of NE is the standard of care which includes broad-spectrum antibacterial 
and antifungal agents as well as intensive supportive care. Due to the very high mortality of surgical 
procedures in patients with prolonged bone marrow aplasia, this approach is used very selectively in 
patients presenting with a refractory septic shock and/or with suspected GI tract perforation. 
AIMS OF THIS STUDY 
The first aim of this study is to describe the clinical presentation, the diagnostic findings, the treatment 
and the outcome of NE. 
The second aim is to explore factors associated with a poor outcome of NE. 
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METHODS 
Study population 
This study describes the presentation and outcome of NE in hemato-oncological patients hospitalized 
in the isolation unit of the Infectious Diseases Service at CHUV for intensive chemotherapy, i.e. 
induction, induction-reinduction, or consolidation for acute leukemia or autologous transplantation of 
hematopoietic stem cells (auto-HSCT) for acute leukemia, lymphoma or myeloma.   
Two study years (2008 and 2012) were selected, because of a similar case-mix with the highest 
numbers of chemotherapy cycles according to the institutional database. All discharge letters were 
screened for standardized key-words associated with NE: “enterocolitis”, “colitis” and “typhlitis”. 
Patients who did not undergo one of the above chemotherapy regimens or in whom colitis was 
associated with an alternative microbiologically documented cause, i.e. Clostridium difficile (positive 
toxin and/or culture) or Cytomegalovirus (multi-level digestive tract injury and detectable viremia) 
infection, were excluded. Data extracted from medical files and discharge letters were collected in a 
clinical report form.  
Neutropenic enterocolitis – diagnostic criteria  
NE is difficult to diagnose on a clinical basis. As there is a lack of consensus regarding the appropriate 
clinical criteria to be fulfilled without confirmatory radiological or pathological examinations, it has 
been suggested to consider levels of diagnostic certainty. Gomez et al. [2] propose a two-level 
classification: possible NE with typical clinical presentation and non-conclusive radiology or 
pathology and certain NE fulfilling clinical and radiological/pathological criteria. In the present study, 
we used the same principle by adding an intermediate level in the classification: possible, probable, 
and definite NE. These levels are characterized by an increasing number of criteria fulfilled among a 
list of five. The first criterion is mandatory: neutropenia defined as a neutrophil count < 0.5 G/l within 
48 hours following fever’s onset. The additional four criteria are described in Table 1: fever, 
symptoms associated with abdominal infection, clinical signs at physical examination of the abdomen 
and radiological or histopathological findings. Two of these four additional criteria were necessary to 
diagnose possible, three for probable and four for definite NE (Figure 1) 
The time of onset of NE was considered as the first day of fever and the time of end as the day of 
resolution of fever, abdominal pain and clinical signs of abdominal infection (Table 1). When the 
improvement of NE was complicated by an infection at a different site, the time of resolution of 
enterocolitis was considered as unknown.   
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Table 1: Neutropenic enterocolitis - Diagnostic criteria. 
 
Figure 1: Neutropenic enterocolitis - Algorithm of diagnostic probability.  
 
 
Analysis 
Data collected from patients treated in 2008 and 2012 were pooled and analyzed with the StataIC 12 
software. A descriptive analysis of the population was performed including demographics, 
hematological malignancy and chemotherapy, infections other then NE, antimicrobial therapy, fungal 
markers and colonisation, presentation, laboratory, microbiological findings, therapy and outcome of 
NE.    
A bivariate analysis was performed to investigate the risk factors of adverse outcome in patients with 
NE by testing its association with variables extracted from the descriptive analysis. Adverse outcome 
Neutropenia (neutrophil count < 0.5G/l)  Mandatory criterion 
Fever (body temperature > 38°C, tympanic thermometer)   
 
 
Additional criteria 
Abdominal infection - symptoms (at least one among abdominal pain, 
diarrhea, bloody stools, vomiting)  
Abdominal infection – signs at physical examination (at least one 
among abdominal tenderness, abdominal distension, peritoneal signs)  
Radiology and/or pathology (bowel wall thickening)  
Neutropenia  
[within 48 hours after fever’s onset] 
+ 2 additional criteria + 3 additional criteria 
 
+ 4 additional criteria 
 
Possible Neutropenic 
Enterocolitis 
Probable Neutropenic 
Enterocolitis 
 
Definite Neutropenic 
Enterocolitis 
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was defined as at least one of the following five events (Table 2): abdominal surgery, severe sepsis, 
septic shock, admission to the intensive care unit, and inhospital mortality. These outcomes were 
considered when they occurred during the course of NE, regardless of a causal relationship with NE. 
When a patient presented two episodes of NE, the second one was considered in the adverse outcome 
analysis to keep possible the occurrence of all five events, in particular of mortality. Fisher’s exact test 
was performed for all binary and categorical variables, whereas median’s equivalence and Wilcoxon-
Mann-Whitney’s test were performed for continous variables. A two-tailed P<0.05 was set for 
statistical significance. 
Table 2: Adverse outcome definition. 
 
Adverse outcome – at least one of the following criteria 
Abdominal surgery 
Severe sepsis 
Septic shock 
Admission to the intensive care unit 
Inhospital mortality 
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RESULTS 
 
Among 199 hemato-oncological patients hospitalized for intensive chemotherapy (i.e. induction, 
induction-reinduction, or consolidation for acute leukemia or autologous transplantation of 
hematopoietic stem cells (auto-HSCT) for acute leukemia, lymphoma or myeloma), 32 (16.1%) 
presented a clinical picture of NE (16.0% in 2008 and 16.1% in 2012), see flowchart (Figure 2). Three 
patients presented two episodes of NE.  
Figure 2: Flowchart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total, patients 
106 (2008) 
93 (2012) 
Exclusions, patients 
No keywords for NE in  
discharge letter 
87 (2008) 
74 (2012) 
 Exclusions, patients 
Other reasons 
2 (2008)  
[chemotherapy (2x)] 
4 (2012)  
[CMV colitis (1x), Clostridium difficile toxin + 
(2x), culture + (1x)] 
Inclusions, patients 
17 (2008 ; 20 episodes) 
15 (2012) 
Keywords for NE in discharge letter : 
« enterocolitis », « colitis », « typhlitis » 
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Population’s demographic characteristics (Table 3) 
Median age was 57 years (range 21 to 69). Men and women were equally represented.  
Most patients underwent intensive chemotherapy for acute myeloid leukemia (AML, 59.4%). At 
admission, 51.4% of patients were in remission of their disease (partial or complete). 37.4% of 
patients were hospitalized after first diagnosis for induction chemotherapy. Refractory (induction-
reinduction) and recurrence of disease were less frequent.   
Median duration of stay in the isolation ward was 31 days (range 19 to 76). Stays exceeding 31 days 
were only found in patients undergoing induction’s chemotherapy.   
Table 3: Population’s demographics and hemato-oncological disease characteristics. 
31 Patients 
Age [years] Median; min - max  57; 21 - 69  
Sex Male n/ N (%)  15/32 (46.9)  
Underlying hematological disease 
AML (including MDS, CML) n/N (%)  
NHL, HL, MM n/N (%)  
ALL, NK n/N (%)  
AML and NHL n/N (%)  
 
18/32 (56.3)  
11/32 (34.4)  
2/32 (6.3)  
1/32 (3.1)  
35 Hospitalizations for intensive chemotherapy = Neutropenic episodes 
Hematological disease - status 
First diagnosis (Induction) n/N (%) 
Refractory disease (Induction-reinduction) n/N (%)  
Remission (partial, complete) n/N (%)  
Recurrence n/N (%)  
 
13/35 (37.1)  
2/35 (5.7) 
18/35 (51.4)  
2/35 (5.7)  
Duration of stay [days] Median; min - max  31; 19 - 76  
AML: acute myeloid leukemia, MDS: myelodysplasic syndrome with blastic transformation, CML: chronic myeloid 
leukemia with blastic crisis, NHL: non-Hodgkin Lymphoma, HL: Hodgkin lymphoma, MM: multiple myeloma, ALL: acute 
lymphoblastic leukemia, NK: blastic plasmacytoid dendritic cells neoplasia. 
Chemotherapy (Table 4) 
Considering all episodes of NE (N=35), induction for acute leukemia (induction1, induction 2, or 
induction followed by reinduction) was the most frequent type of chemotherapy (23/35, 65.7%).  
Cytosine arabinoside (cytarabine) was administered in 31/35 (88.6%) chemotherapy cycles. Cytosine 
arabinoside was not administered in 4 chemotherapy cycles, which included auto-HSCT for multiple 
myeloma (n=3) and another regimen for blastic plasmacytoid dendritic cells neoplasia (n=1). The dose 
of cytarabine varied from 1’260 to 13’400 mg/m2 depending on the underlying hematological disease 
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and the type of chemotherapy (example of induction 1 therapy: cytarabine + idarubicine (low-dose 
cytarabine), example of induction 2 therapy: cytarabine + amsacrine (high-dose cytarabine), example 
of induction-reinduction therapy: cytarabine + idarubicine, directly followed, without recovery from 
medullar aplasia, by cytarabine + amsacrine (high-dose cytarabine)). Among patients treated with 
cytarabine containing regimens, 16.1% developed a severe rash (cutaneous toxicity) requiring 
systemic corticosteroids. The median onset of rash was on day 12 after onset of chemotherapy and its 
duration was between 3 and 14 days. Patients receiving high-dose cytarabine were more likely to 
develop a rash (P=0.042).    
All patients received multi-drug regimens except three patients undergoing auto-HSCT for MM 
(melphalan).  
Table 4: Chemotherapy. 
Type of chemotherapy  
Induction 1 n/N (%)  
Induction 2 n/N (%) 
Induction + reinduction n/N (%)  
Auto-HSCT n/N (%)  
 
11/35 (31.4)  
10/35 (28.6) 
2/35 (5.7)  
12/35 (34.3)  
Cytotoxic drugs  
Cytarabine n/N (%)  
Clofarabine n/N (%)  
Anthracycline (idarabucine, amsacrine, daunorubicine) n/N (%)  
Alkylating agent (melphalan, carmustine, cyclophosphamide) n/N (%)  
Topoisomerase inhibitor (etoposide) n/N (%)  
Other (vincristine, tretinoid) n/N (%)  
 
31/35 (88.6)  
2/35 (5.7) 
24/35 (68.6)  
12/35 (34.3)  
9/35 (25.7)  
2/35 (5.7)  
Cytarabine  
Dose [mg/m2] Median; min - max  
 
1600; 1260 - 13'400 (N=31)  
Cytarabine Rash (requiring systemic corticosteroids) 
Rash n/N (%)  
ARAC dose if rash present [mg/m2] Median; min-max 
Onset [days post chemo] Median; min - max  
Duration of rash [days] Median; min - max  
 
5/31 (16.1)  
12’000; 1400 – 13’400 (N=5) 
12; 2 – 25 (N=5)  
8; 3 – 14 (N=5)  
Auto-HSCT:  Autologous hematopoietic stem cells transplantation 
Infections, antibacterial and antifungal drugs prior to NE (Table 5) 
Prior to NE, 34.3% of patients had presented an episode of infection: fever with intestinal mucositis 
was one of the most frequent infections preceding NE (40.0% of all infectious episodes previous NE, 
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N=16). Antibacterial and antifungal drugs had been administered to 34.3% and 37.1% of patients, 
respectively. Antibacterial agents were only administered for therapy of infections, while no 
antibacterial prophylaxis was used. Fluconazole was the most prescribed antifungal drug, principally 
as prophylaxis in selected high-risk patients with AML (e.g. induction chemotherapy).  
63.6% and 97.0% of patients had oral and/or intestinal mucositis, respectively. The onset of intestinal 
mucositis was very close to the onset of NE (median delay 2 days, range -14 to 15). Its median 
duration was 11 days (range 4 to 34).  
Table 5: Infections, antibacterial and antifungal drugs prior to NE.  
Antibacterial and/or antifungal drugs prior to NE 
n/N (%)  
 
18/35 (51.4)  
Antibacterial drugs prior to NE  
n/N (%)  
 
12/35 (34.3)  
Antifungal drugs prior to NE 
n/N (%) 
Antifungal prophylaxis n/N (%) 
Fluconazole n/N (%) 
Voriconazole n/N (%) 
Liposomal amphotericin B n/N (%)  
 
13/35 (37.1)  
10/35 (28.6) 
11/35 (31.4)  
2/35 (5.7)  
1/35 (2.9)  
Infections prior to NE  
MDI-B n/N (%)  
MDI-nB n/N (%)  
CDI n/N (%)  
FUO n/N (%)  
 
2/35 (5.7)  
5/35 (14.3)  
6/35 (17.1)  
4/35 (11.4)  
Mucositis  
Oral n/N (%)  
Intestinal n/N (%)  
Oral and Intestinal n/N (%) 
Intestinal mucositis 
Onset [days post onset of chemo] Median; min - max  
Duration [days] Median; min – max  
Delay between onset and onset of NE Median; min – max  
 
21/33 (63.6) (2 missing)  
32/33 (97.0) (2 missing)  
21/33 (63.6) (2 missing) 
 
7; -3 – 26 (N=32)  
11; 4 – 34 (N=32)  
2; -14 – 15  
MDI-B: microbiologically documented infection with bacteremia, MDI-nB: microbiologically documented infection without 
bacteremia, CDI: clinically documented infection, FUO: fever of unknown origin 
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Immunosuppression, fungal colonization and fungal markers (Table 6) 
51.4% of patients received corticosteroids before the onset of NE, most frequently (66.7%) as part of 
intensive chemotherapy before auto-HSCT (other indications: cytarabine rash, trans-retinoic acid 
syndrome).  
73.5% and 70.4% of patients have positive oropharynx and/or stool cultures for yeasts, respectively. 
Candida albicans was the most frequent colonizer: 92.0% and 94.7% of positive oropharynx and stool 
cultures, respectively. Other yeasts and molds were also isolated: Candida glabrata (oropharynx (O), 
stools (S)), Candida guillermondii (O), Candida dubliniensis (O), Candida krusei (S), Candida 
tropicalis (S), Geotrichum spp (S), Saccharomyces cerevisiae (S) and Aspergillus niger (S). Cultures 
were reported positive for the first time after the onset of NE in 96.0% patients.   
Only one patient showed positive fungal markers (positive galactomannane, then positive mannane 
and anti-mannane antibodies): in this patient a probable invasive pulmonary aspergillosis and a 
possible hepatosplenic candidiasis was diagnosed. Anti-mannane antibodies were positive at 
admission in two patients and remained positive: these results represented a previous seroconversion 
and were not correlated with a diagnosis of invasive mycosis during the hospital stay.     
Table 6: Immunosuppression, fungal colonization and fungal markers.  
Corticosteroids  
Administration n/N (%)  
Dose (prednisone equivalent) [mg/day] Median; min - max  
 
18/35 (51.4)  
156; 14 – 156 (N=18)  
Yeast colonization  
Oropharynx 
Yeast colonization n/N (%)  
Time between colonization and onset NE Median; min – max  
Colonization prior NE n/N (%)  
Candida albicans n/N (%)  
Stools 
Yeast colonization n/N (%)  
Time between colonization and onset NE Median; min – max  
Colonization prior NE n/N (%)  
Candida albicans n/N (%)  
 
 
25/34 (73.5)  
0; -14 - 17  
12/25 (48.0)  
23/25 (92.0) 
 
19/27 (70.4)  
0; -9 - 24  
6/19 (31.6)  
18/19 (94.7)  
Yeasts other than Candida spp 
Stools culture species  
Geotrichum spp n/N (%) 
Aspergillus niger n/N (%) 
 
 
3/35 (8.6) 
2/35 (5.7) 
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Saccharomyces cerevisiae n/N (%)  3/35 (8.6) 
Fungal markers  
Galactomannane positive n/N (%) 
Mannane positive n/N (%) 
Anti-mannane positive n/N (%)  
 
1/28 (3.6) (7 missing)  
1/28 (3.6) (7 missing)  
3/28 (10.7) (7 missing)  
Positivity cut-offs 
Galactomannane:  0.25 – 0.5 [index] 
Mannane:   2008  0.25 – 0.5 [ng/ml] 
    2012  62.5 – 125 [pg/ml]  
Anti-mannane antibodies: 0 – 5 [UA/ml] 
 
Clinical presentation of NE (Table 7)   
The median onset of NE was on day 9 after onset of chemotherapy (for patients undergoing auto-
HSCT, median onset was on day 3 post transplantation) and on day 1 of neutropenia. The median 
duration of NE was 12.5 days (range 3 to 59).   
All patients presented the following triad: neutropenia, fever and digestive symptoms. Diarrhea was 
observed in all patients. 88.6% of patients presented with abdominal signs at physical examination: 
82.9% abdominal tenderness, 60% peritoneal signs, 40.0% at the classical localization in the right 
lower quadrant. 45.7% of patients had positive radiology and/or pathology findings. According to the 
diagnostic classification used in the present study (Figure 1), 54.3% of patients had probable, 40% 
definite, and 5.7% possible NE. Among probable cases, most presented the previously described triad 
with abdominal signs at physical examination.   
Table 7: Clinical presentation of NE 
Inclusion criteria  
Neutropenia n/N (%)  
Fever n/N (%)  
Digestive symptoms n/N (%)  
Abdominal signs n/N (%)  
Positive radiology and/or histopathology n/N (%)  
Positive radiology n/N (%) 
Positive pathology n/N (%) 
Possible NEb  n/N (%)  
Probable NEb n/N (%)  
 
35/35 (100.0)  
35/35 (100.0)  
35/35 (100.0)  
31/35 (88.6)  
16/35 (45.7)  
16/35 (45.7) 
1/35 (2.9) 
2/35 (5.7)  
19/35 (54.3)  
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Definite NEb n/N (%)  14/35 (40.0)  
Neutropenic enterocolitis chronology  
Onset [days post chemo] Median; min - max  
Onset [days post auto-HSCT] Median; min - max  
Onset [days post neutropenia] Median; min - max  
Duration [days] Median; min – max  
 
9; 1 – 29 
3; 1 – 8 (23 missing) 
1; -2 - 31 
12.5; 3 – 59 (3 missing a)  
Symptoms / signs  
Fever n/N (%)  
Abdominal pain n/N (%)  
Diarrhea n/N (%)  
Vomiting n/N (%)  
Bloody stools n/N (%)  
Abdominal tenderness n/N (%)  
Peritoneal signs n/N (%)  
Localization in right lower quadrant n/N (%)  
 
35/35 (100.0)  
30/35 (85.7)  
35/35 (100.0)  
19/35 (54.3)  
6/35 (17.1)  
29/35 (82.9)  
21/35 (60.0)  
14/35 (40.0)  
a: end of NE unknown 
b: definition: see figure 1 
Laboratory and radiological findings in NE (Table 8) 
All patients were in agranulocytosis at the time of NE diagnosis (median duration 10 days, range 0 to 
34 days). C-reactive protein was elevated (median: 214.5 [mg/l], range 23 – 472 [mg/l]). Two patients 
presented with an elevated lactatemia (> 2 mmol/l) and both died. 
62.9% patients had a CT scan. The most frequent radiological sign of NE was bowel wall thickening 
(BWT, more than 4mm): in 64.3% patients BWT was more than 10 mm. BWT was more frequently 
located in the right colon or ileocecal region (42.9%), followed by small bowel (35.7%), right and left 
colon (14.3%) and small bowel plus colon (7.1%). Infiltration of adipose tissue (50.0%) and ascites 
(45.5%) were also observed. In six patients with clinical diagnosis of probable NE (neutropenia, fever, 
abdominal symptoms and signs), no radiological BWT or other indirect sign of NE was found. 
Table 8: Laboratory and radiological findings in NE.   
Laboratory  
Agranulocytosis n/N (%)  
Duration [since admission] [days] Median; min - max  
Neutropenia n/N (%)  
Duration [since admission] [days] Median; min - max  
CRP maximal value [mg/l] Median; min - max  
 
35/35 (100.0)  
10; 0 - 34 
35/35 (100.0)  
14; 6 – 41 (3 missing a) 
214.5; 23 – 472 (9 missing)  
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PCT maximal value [µg/l] Median; min - max  
Lactate more than 2 mmol/l n/N (%)  
0.62; 0.12 - 24.3 (20 missing)  
2/35 (5.7)  
Radiology  
CT n/N (%)  
Abdominal CT  
Bowel wall thickening (> 4 mm) n/N (%)  
Infiltration of adipose tissue n/N (%)  
Ascites n/N (%)  
Mesenteric/retroperitoneal adenopathies n/N (%)  
Periportal oedema n/N (%)  
Gall bladder hydrops/distention n/N (%)  
Intestinal dilatation n/N (%)  
Parietal contrast enhancement n/N (%)  
No signs for NE n/N (%) 
Thoracic CT 
Pulmonary infiltrate/lesion n/N (%)  
Pleural effusion n/N (%)  
 
22/35 (62.9)  
 
14/22 (63.6) (N=22)  
11/22 (50.0) (N=22)  
10/22 (45.5) (N=22)  
8/22 (36.4) (N=22)  
6/22 (27.3) (N=22)  
3/22 (13.6) (N=22)  
2/22 (9.1) (N=22)  
2/22 (9.1) (N=22) 
6/22 (27.3) 
 
7/22 (31.8) (N=22)  
3/22 (13.6) (N=22)  
a : 1 case : neutropenia at admission, 2 cases : neutropenia at discharge (including one death) 
Reference ranges 
Agranulocytosis: neutrophile count < 0.1G/l 
Neutropenia: neutrophile count < 0.5 G/l 
C reactive protein (CRP):  < 10 [mg/l] 
Procalcitonine (PCT):  0.25 – 0.5 [µg/l]  localized bacterial infection 
   0.5 – 2 [µg/l]  systemic bacterial infection 
   > 2 [µg/l]  association with septic state 
Lactate:    < 2 [mmol/l] 
 
Microbiological documentation of NE (Table 9) 
Blood cultures from central venous catheter and peripheral venipuncture were performed at the onset 
of all episodes of NE. Bacteremia was detected in 34.3% patients: Gram negative rods, Gram positive 
cocci and fungi were isolated. In several cases a concomitant central venous catheter infection was 
present (bacteremia with Staphylococcus epidermidis). One patient presented a mixed polymicrobial 
infection: peripheral blood cultures were positive for Candida albicans (1/4 bottles, 1/2 sets, i.e. 
proven invasive fungal infection according to EORTC/MSG) and central catheter blood cultures were 
positive for Klebsiella (oxytoca group) (1/4 bottles, 1/2 pairs).  
In one case, Enterococcus faecalis was detected in the bile culture. This patient presented a 
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neutropenic duodenitis with stenosis of Vater’s papilla (sample of bile collected during 
sphincterotomy and stenting of biliary duct).  
Table 9: Microbiological documentation of NE. 
Microbiology  
Blood cultures  
Blood culture sampled n/N (%)  
Blood culture positive n/N (%)  
FUNGI 
Candida albicans n/N (%) 
GRAM-NEGATIVES 
Enterobacter cloacae n/N (%) 
Escherichia coli n/N (%) 
Klebsiella (oxytoca group) n/N (%) 
GRAM-POSITIVES 
Enterococcus faecalis n/N (%) 
Enterococcus faecium n/N (%) 
Staphylococcus aureus n/N (%) 
Staphylococcus epidermidis n/N (%) 
Staphylococcus haemolyticus n/N (%) 
Streptococcus mitis n/N (%) 
Streptococcus pneumoniae n/N (%) 
Streptococcus vestibularis n/N (%) 
Peptostreptococcus n/N (%) 
Other cultures (bile) 
Enterococcus faecalis n/N (%)  
 
 
35/35 (100.0) 
12/35 (34.3) 
 
1/35 (2.9) 
 
1/35 (2.9) 
4/35 (11.4)  
1/35 (2.9)  
 
2/35 (5.7) 
2/35 (5.7) 
1/35 (2.9) 
2/35 (5.7) 
1/35 (2.9) 
1/35 (2.9) 
1/35 (2.9) 
1/35 (2.9) 
1/35 (2.9) 
 
1/ 35(2.9) 
 
 
Medical and surgical management of NE (Table 10) 
All patients received broad-spectrum antibacterial drugs from the onset of symptoms for a median 
duration of 19.5 days. 82.9% of patients were treated with antifungal drugs (in a majority fluconazole 
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was switched to broad-spectrum agents: caspofungin, amphotericin B or voriconazole), sometimes 
with a delay from the beginning of symptoms because of clinical deterioration or lack of improvement 
despite appropriate antibiotics.   
Opiates were prescribed as symptomatic treatment of abdominal pain. Medical therapy was completed 
by hemodynamic support, nutritional support (nasogastric tube) and bowel rest (parenteral nutrition). 
  
Only two patients underwent surgical therapy during hospitalization: in one NE was the indication for 
surgery (duodenitis requiring sphincterotomy of Vater’s papilla and stenting of biliary duct).  
Table 10: Medical therapy of NE. 
Medical therapy 
Antimicrobial drugs 
Delay between onset NE and antimicrobial drugs [days] Median; min - max  
Antibacterial drugs 
 n/N (%)  
Duration [days] Median; min – max  
Delay between onset NE and antibiotics [days] Median; min - max  
Antifungal drugs 
 n/N (%)  
Duration [days] Median; min – max  
Delay between onset NE and antifungal drugs [days] Median; min – max  
Fluconazole n/N (%)  
Voriconazole n/N (%)  
Liposomal amphotericin B n/N (%)  
Caspofungine n/N (%)  
Other medications 
Opiates n/N (%)  
 
 
0; 0-0 
 
35/35 (100.0)  
19.5; 8 – 54 (N=34, 1 missing a)  
0; 0 - 1  
 
29/35 (82.86) 
15.5; 4 – 65 (N=26, 3 missing a)  
1; 0 – 13 (N=29) 
23/29 (79.3)  
10/29 (34.5)  
7/29 (24.1)  
20/29 (69.0) 
 
26/35 (74.3)  
a:  end of treatment unknown 
Outcome of NE (Table 11) 
Seven of 35 patients (20%) showed an adverse outcome (23.5% in 2008, 20.0% in 2012): one fulfilled 
the criteria for possible, three for probable, and three for definite NE.  
One patient developed an ileus. None presented an intestinal perforation. One patient presented both a 
possible invasive candidiasis and a probable invasive aspergillosis and one a proven invasive 
candidiasis (positive blood cultures for Candida albicans and hepatosplenic lesions on CT). Three 
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patients presented a second episode of NE during a subsequent chemotherapy cycle.  
Six of 35 patients (17.1%) were transferred to the intensive care unit for sepsis associated with NE or 
for other reasons than NE (bleeding, sepsis associated with another infection).   
Two patients died during hospitalization (inhospital mortality: 5.7%) due to septic complications: one 
death was attributed to NE and one to pulmonary legionellosis. 
Table 11: Outcome of NE.  
Outcome  
Severe sepsis n/N (%) 
Septic shock n/N (%)  
Multiple organ failure n/N (%) 
ICU transfer n/N (%)  
Duration of ICU stay [days] Median; min - max  
Ileus n/N (%) 
Intestinal perforation n/N (%) 
Surgery n/N (%) 
 
Recurrence of NE (3 months, during following cure) n/N (%)  
Proven invasive candidiasis with hepatosplenic lesions (3 
months) n/N (%) 
Possible hepatosplenic candidiasis and probable pulmonary 
aspergillosis (3 months) n/N (%) 
Mortality [30 days and inhospital] n/N (%)  
 
4/35 (11.4)  
2/35 (5.7)  
2/35 (5.7) 
6/35 (17.1)  
4.5; 1 – 16, (N=6, 29 missing)  
1/35 (2.9)  
0/35 (0.0)  
1/35 (2.9)  
Sphincterotomy and stenting of biliary duct 
6/35 (17.1) 
1/35 (2.9) 
 
1/35 (2.9) 
 
2/35 (5.7)  
Factors associated with adverse outcome of NE (Tables 12, 13, 14) 
By bivariate analysis, several factors were statistically associated with adverse outcome of NE (Table 
12). Patients with NE and acute leukemia, in particular those undergoing induction-reinduction 
chemotherapy, those receiving high-dose cytarabine (third tertile of the dose distribution) and 
presenting a severe cytarabine rash (requiring a treatment with systemic corticosteroids), and those 
with a longer duration of agranulocytosis, had more frequently an adverse outcome.    
Patients presenting fever and intestinal mucositis (CDI) before the onset of NE developed more 
frequently septic complication. Patients with documented bacteremia during NE had more frequently 
an adverse outcome. By contrast, patients presenting adipose tissue infiltration on CT scan had a better 
outcome than those who did not. Moreover, BWT was not significantly associated with the outcome. 
Using more sensitive statistical tests for continous variables (Table 14), other factors appeared to be of 
significance. A low body mass index and a long duration of NE increased the risk of adverse outcome. 
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Other factors showed non-significant trends for an association with adverse outcome (Table 13): 
female sex, old age, infection prior to NE (without distinction of site and etiology), antibiotics and/or 
antifungal drugs prior to NE, prolonged antibacterial and broad-spectrum antifungal therapy for NE, 
patients admitted to or discharged from the isolation unit with neutropenia. Antifungal prophylaxis did 
not seem to protect from adverse outcome.    
Table 12: Adverse outcome - statistically significant associations. 
 Overall Poor outcome (line %) Exact  
Fisher’s test 
p-value  n % 
Hematological disease (N=32) 
Double diagnosis [LMA, LNH]  
LLA, NK 
LMA [included LMC, SMD] 
LH, LNH, MM 
 
1 
2 
18 
11 
 
1 
1 
4 
0 
 
100.0  
50.0 
22.2 
0.0 
0.034  
 
 
 
 
Type of chemotherapy (N=32) 
Induction 1 
Induction 2 
Induction-reinduction 
Auto-HSCT  
 
8 
10 
2 
12 
 
1 
3 
2 
0 
 
12.5 
30.0 
100.0 
0.0 
0.007  
CDI prior NE  (N=32) 
Yes 
No 
 
5 
27 
 
3 
3 
 
60.0 
11.1 
0.034  
Severe cytarabine rash (requiring systemic 
corticosteroids) (N=28) 
Yes 
No 
 
 
5 
23 
 
 
4 
1 
 
 
80.0 
4.4 
0.002  
Cytarabine dose [tertiles of distribution] (N=32) 
1 [1260 - 1520 mg/m2]  
2 [1521 - 1600 mg/m2] 
3 [1601 - 13’4000 mg/m2] 
 
8 
9 
11 
 
0 
0 
5 
 
0.0 
0.0 
45.4 
0.007  
Bacteremia during NE (N=32) 
Yes 
No 
 
12 
20 
 
5 
1 
 
41.7 
5.0 
0.018  
Duration agranulocytosis [tertiles of distribution] (N=32) 
1 [0 – 5 days] 
2 [6 – 11 days] 
3 [12 -34 days] 
 
9 
11 
12 
 
0 
1 
5 
 
0.0 
9.1 
41.7  
0.050  
CT - Infiltration of adipose tissue (N=19) 
Yes 
No 
 
9 
10 
 
0 
6 
 
0.0 
60.0 
0.011  
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Table 13: Adverse outcome - not statistically significant trends. 
 
Overall 
Poor outcome (line %) Exact 
Fisher’s 
test 
p-value  
n % 
BMI (N=32) 
<18.5 kg/m2 
>=18.5 & <=25 kg/m2 
>25 & <=30 kg/m2 
>30 kg/m2  
 
2 
12 
13 
5 
 
1 
4 
1 
0 
 
50.0 
33.3 
7.7 
0.0  
0.147  
Sex (N=32) 
Female 
Male  
 
17 
15 
 
5 
1 
 
29.4 
6.7 
0.178  
Age related to median [Halves of distribution] (N=32) 
1 (<57 years) 
2 (>=57 years)  
 
14 
18 
 
1 
5 
 
7.1 
27.8 
0.196  
Infections (MDIB, MDInB, CDI, FUO) prior to NE (N=32) 
Yes 
No 
 
10 
22 
 
4 
2 
 
40.0 
10.0 
0.060  
Antibacterial or antifungal drugs prior to NE (N=32) 
Yes 
No 
 
15 
17 
 
5 
1 
 
33.3 
5.9 
0.076  
Antibacterial drugs prior to NE (N=32) 
Yes 
No 
 
10 
22 
 
4 
2 
 
40.0 
9.1 
0.060  
Antifungal drugs prior to NE (N=32) 
Yes 
No 
 
11 
21 
 
4 
2 
 
36.4 
9.5 
0.148  
Duration of neutropenia (N=32) 
Tertiles of distribution 
1 [6 – 8 days] 
2 [9 – 18 days] 
3 [19 – 41 days] 
Neutropenia at admission or discharge  
 
 
8 
11 
10 
3 
 
 
0 
1 
3 
2 
 
 
0.0 
9.1 
30.0 
66.7 
0.053  
Abdominal CT-scan (N=32) 
Yes 
No 
 
19 
13 
 
6 
0 
 
31.6 
0.0 
0.059  
Duration of NE [tertiles of distribution] (N=30) 
1 [3 – 8 days] 
2 [9 – 15 days]  
3 [16 – 59 days] 
 
9 
9 
12 
 
0 
1 
4 
 
0.0 
11.1 
33.3 
0.149  
Antifungal drugs  NE (N=32) 
Yes 
No 
 
26 
6 
 
6 
0 
 
23.1 
0.0 
0.564  
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Broad-spectrum antifungal drugs  NE (N=26)  
Yes 
No 
 
18 
8 
 
5 
1 
 
27.8 
12.5 
0.628 
Duration antifungal drugs  NE [tertiles of distribution] (N=23) 
1 [4 – 9 days] 
2 [10 – 30 days] 
3 [31 – 65 days] 
 
10 
10 
3 
 
1 
3 
1 
 
10.0 
30.0 
33.3  
0.498  
Duration antibacterial drugs NE [tertiles of distribution] (N=31) 
1 [8 – 13 days] 
2 [14 – 26 days] 
3 [27 – 54 days] 
 
7 
13 
11 
 
0 
3 
2 
 
0.0 
23.1 
18.2  
0.588  
 
 
 
 
Table 14: Adverse outcome – continous variables analysis. 
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BMI 0.147  0.172  0.0263  
Age 0.196  0.194  0.1532  
Cytarabine dose 0.007  0.005  0.0025  
Duration of neutropenia 0.053  0.279  0.0569  
Duration of agranulocytosis 0.050  0.172  0.0050  
Onset of NE post chemotherapy 0.497  0.383  0.1578  
Duration of NE 0.149  0.042  0.0165  
Duration antibacterial drugs prior to NE 0.229  0.524  0.1087  
Duration antifungal drugs prior to NE 0.200  1.000  0.8501  
Duration antibacterial drugs NE 0.588  0.654  0.5013  
Duration antifungal drugs NE 0.498  0.618  0.2470  
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DISCUSSION 
Incidence - Population characteristics  
In the present study, 32/199 (16.0%) of hemato-oncological patients hospitalized in the isolation unit 
for intensive chemotherapy developed a clinical picture of NE.   
This incidence is higher than that expected according to recent reviews. Gorschlüter et al. reported an 
incidence of 5.6% in patients treated for acute leukemia [4]. This can be explained by differences in 
the diagnostic definition of NE. Our study did not require radiological or pathological criteria for 
inclusion: clinical criteria were meant to cover a broader spectrum of the presentation of NE which 
might contribute to the identification of factors associated with severe forms and adverse outcome. 
Acute myeloid leukemia was the most frequent underlying hematological disease in our population. 
According to the literature, the subgroup of patients suffering from acute leukemia is at higher risk to 
develop NE [4] due to aggressive chemotherapy regimens resulting in toxic mucositis, profound and 
long-duration neutropenia, and, prolonged use of antibiotics. Patients undergoing induction or 
induction-reinduction chemotherapy (refractory disease) for acute leukemia followed by prolonged 
neutropenia represented also the majority of the cases of NE in the present study.   
 
Clinical presentation  
The classical triad fever-abdominal pain-diarrhea was observed in 85.7% of our patients with NE [2]. 
Other authors reported similar data [17] in patients with solid tumors or hemato-oncological cancers 
who were neutropenic on admission or during therapy. In the present study, 82.9% patients presented 
abdominal tenderness, 60.0% peritoneal signs and 40.0% pain localized in the right lower quadrant, as 
classical clinical signs of NE. NE is difficult to diagnose based on clinical presentation, which can be 
confounded by concomitant infections at different sites or non-infectious conditions associated with 
the underlying disease or the chemotherapy.   
Clinical symptoms and signs of NE are largely variable: some forms of NE have been diagnosed by 
CT scan imaging despite a very mild clinical picture, emphasizing the lack of sensitivity of the 
classical clinical presentation [18].  
Abdominal symptoms/signs of infection suggest NE or intestinal mucositis: one might question 
whether these two clinical entities can be differentiated. In our study population, 97% of NE patients 
did present intestinal mucositis. Interestingly, the median delay between the onset of intestinal 
mucositis and NE was 2 days. This shows that intestinal mucositis is the first step of NE as a 
continuum of a common pathogenesis. Considering the wide range of severity, the clinical 
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presentation and other factors might help the physician to identify patients at particular risk to develop 
an adverse outcome.  
 
Figure 4 A common pathological pathway of intestinal mucositis and NE. 
 
  
 
 
 
 
 
 
 
 
 
Microbiological findings  
In one third of NE patients, blood cultures were positive for bacteria (Gram-negative rods or Gram-
positive cocci). In several cases infection was polymicrobial and in one patient concomitant 
bacteremia and fungemia were documented. These microbiological data are similar to those described 
in the literature [11] and confirm the role of the intestinal flora in the pathogenesis of NE.   
In more than two thirds of patients gastrointestinal tract colonization by yeasts (Candida albicans was 
the most frequent colonizer) or rarely molds (Aspergillus spp) was documented. Their role in the 
pathogenesis has been demonstrated in the literature by the documentation of fungal and mixed 
bacterial-fungal invasion involving Candida spp and Aspergillus spp in rare cases of NE [16]. 
However, the majority of the reported episodes of NE are of bacterial etiology. This is consistent with 
the findings in our study: two episodes of invasive candidiasis (5.7% of all NE) have been 
documented. In addition, fungal markers might fail to detect localized forms of fungal NE because of 
their lack of sensitivity in the absence of hematogenous dissemination. 
Intestinal Mucositis 
Febrile intestinal 
mucositis  
Neutropenic 
enterocolitis 
Necrotic 
enterocolitis 
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Laboratory findings  
Neutropenia was present in all patients. Its duration was variable depending on the chemotherapy 
regimen (shorter in auto-HSCT than in acute leukemia).  
Inflammatory markers such as C-reactive protein and procalcitonine were not measured in all patients, 
but were found significantly elevated in patients with severe forms of NE and adverse outcome.  
Two critically ill patients presented a high lactate level in the context of septic shock:  both died.
  
Radiological findings  
Some authors consider that CT scan is needed for confirmation of NE [19]. Gorschlüter et al. reported 
bowel wall thickening, a typical sign of NE, in a patient with the clinical diagnosis of intestinal 
mucositis [13], highlighting the continuum in the pathogenesis between these two entities. Less than 
two thirds of patients underwent an abdominal CT scan in the present study. This reflects the 
indications applied in our practice for CT imaging in febrile neutropenic patients with abdominal 
symptoms/signs: lack of clinical improvement after appropriate antibacterial and antifungal therapy, 
suspected local complications such as perforation or persistent fever with suspected invasive fungal 
infection. Two thirds of patients examined by abdominal CT scan presented bowel wall thickening 
more than 4 mm (BWT): in two thirds BWT exceeded 10 mm (cf. illustrations in Appendix 1). Cartoni 
et al. associated a BWT of more than 10 mm with adverse outcome of NE [12]. Other frequent CT 
signs associated with NE in our study and previously described in the literature were infiltration of 
adipose tissue, ascites and mesenteric/retroperitoneal adenopathies. In the remaining third of patients 
CT scan imaging did not reveal bowel wall thickening (BWT). These patients presented very 
suggestive clinical findings (fever, abdominal tenderness and peritoneal signs), which were classified 
as probable NE: these cases might represent non-severe forms of NE. On the other hand, these 
negative CT finding were issued from routine interpretation and imaging have not been read at second 
look by senior radiologists.  
 
Medical and surgical therapy  
All but one patient were treated conservatively. The management of NE included broad-spectrum 
antibacterial agents, hemodynamic support, and symptomatic treatment (mainly opioids). The majority 
of patients also received antifungal agents: therapy was started during the course of NE or ongoing 
prophylaxis was either modified for a broad-spectrum agent or continued unchanged. Parenteral or 
naso-gastric tube nutrition was administered in some patients.  
No surgical bowel resection or exploratory laparotomy was performed.      
A patient with duodenitis and mechanical cholestasis underwent an interventional endoscopic drainage 
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and recovered.  
These management practices reflected the recent recommendations for an intensive conservative 
management with strict indications for surgical interventions in presence of local complications or 
bleeding [19, 20].    
 
Morbidity / Mortality  
In our study, the inhospital mortality was very low (5.7%) compared to the literature (up to 50.0-
100.0% [1]). This ten- to twentyfold difference might be explained by the inclusion of milder forms of 
NE in our study and/or reflect differences in type and timing of conservative and antimicrobial 
management. 10% of patients developed a severe sepsis during the course of NE and two (5.7%) 
presented a septic shock and died: in one patient death was attributed to the complications of NE and 
in the second to a microbiologically documented lung legionellosis.    
20% of patients presented an adverse outcome, i.e. at least one of the following events: abdominal 
surgery, severe sepsis, septic shock, admission to the intensive care unit, or inhospital mortality. 
Several factors were found to be associated with adverse outcome in a bivariate analysis. The majority 
of them reflect a common denominator in patients with the hematological diagnosis of acute myeloid 
leukemia. Induction or induction-reinduction chemotherapy with high-dose cytarabine results in 
intestinal mucositis and prolonged agranulocytosis, which are associated with severe infection and 
bloodstream dissemination. In addition, the association found between low BMI and adverse outcome 
of NE might reflect an increased individual vulnerability to severe complications or simply be the 
consequence of a prolonged critically ill status due to such a severe condition. These findings are 
confirmed in the literature: hematological and mucosal toxicity associated with high-dose cytarabine 
has been described as a major risk factor for NE in hemato-oncological patients [2-3]. While these 
factors associated with adverse outcome are not modifiable, they help to identify high-risk patients 
who need a very close follow-up in presence of symptoms/signs of abdominal infection and who 
might benefit of primary antibacterial and antifungal prophylaxis. 
Due to the low number of patients, the retrospective and observational design, and the heterogeneity of 
the sample, we were unable to draw conclusions on the impact of treatment strategies on the outcome 
of NE, for example, the role of broad-spectrum antifungal drugs. Although proven or probable IFI are 
rare in the setting of NE, as confirmed by our findings, antifungal therapy is often administered 
empirically. This approach is based on the recommendation that an IFI should be suspected in patients 
with persistent neutropenic fever and symptoms/signs of infection despite broad-spectrum antibiotics. 
Thus, in the presence of severe NE, the administration of an antifungal therapy with a fungicidal affect 
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on Candida (echinocandin or amphotericin B) is consistent with these recommendations [21, 22]
  
Critical analysis of methods and results  
This study is characterized by numerous limitations.   
The first limitation is the definition of NE. We included all patients with a clinical diagnosis of NE in 
the discharge letter based on standardized key words. In some patients CT scan imaging had not been 
not performed or failed to confirm a BWT as major criterion of NE: a merely clinical diagnosis might 
have overestimated the incidence of NE or resulted in the inclusion of less severe cases of NE. 
Conversely, a systematic review of CT imaging by senior radiologists for improving the accuracy of 
the radiological findings was not performed: a more careful reading might have detected additional 
cases with BWT which might have been missed in the routine interpretation by less experimented 
radiologists. Further, the used selection key words might have missed cases of NE, e.g. those reported 
in the discharge letter with a diagnosis of intestinal mucositis with fever. Moreover, the different 
diagnostic criteria used in the literature make comparisons of findings and outcomes very difficult.  
The decision to study two years over a discontinued period was based on the similar case-mix with a 
high number of chemotherapy cycles at risk of NE: this might have been a source of selection bias 
resulting in data not reliably reflecting the epidemiology, e.g. with an overestimation of the incidence 
and severity of NE. However, the potential of bias is probably limited because the hemato-oncological 
population hospitalized in the isolation ward, the chemotherapy regimens, and the management of 
infections remained unchanged over the years. The similar incidence rates of NE (16%) and of adverse 
outcomes (20%) observed in 2008 and 2012 confirm that these data are probably representative of the 
five-year period.   
The small number of patients resulting in a limited power of statistical analyses is an important 
limitation. In addition, the multiplicity of statistical tests was not taken into account, which might have 
overestimated the significance of some results. This study is thus merely exploratory and results of 
statistical analyses need to be carefully interpreted. Finally the findings on factors associated with 
adverse outcome were derived from a bivariate analysis, because the multivariate approach was not 
applicable in such a limited sample size.   
Strengths of the present study in patients with NE are: i) the findings on a rare life-threatening medical 
condition for which few data are available in adult patients receiving intensive chemotherapy, ii) the 
identification of factors associated with adverse outcome which might have practical consequences on 
prevention and management of NE in high-risk patients.   
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CONCLUSION 
 
In conclusion, this exploratory study points to the determinant role of intensive chemotherapy for 
acute myeloid leukemia and especially of high-dose cytarabine in the occurrence of NE. The 
hematological and mucosal toxicity resulting in prolonged agranulocytosis and severe intestinal 
mucositis are major components in the pathogenesis of NE and are associated with severe forms and 
adverse outcome. These findings may help the physician to identify the patients at high risk to develop 
complications who need a prompt management with close follow-up and maybe antimicrobial 
prophylaxis.   
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APPENDIX 1- CT scan imaging in two patients with NE. 
 
 
